Articles from Secretome Therapeutics

Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that it will present at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco, California.

Secretome Therapeutics today announced the launch of a Phase 1, dose-escalating trial of STM-01, Secretome’s neonatal cardiac progenitor cell (nCPC) product, for the treatment of heart failure in young adults with dilated cardiomyopathy (DCM). This trial, and a subsequent dose-escalating Phase 1 of STM-01 in pediatric DCM, are funded through a grant from The Marcus Foundation and will take place at Children’s Healthcare of Atlanta.

Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, MD, as Chief Medical Officer. Dr. Warren is a highly experienced pharmaceutical executive with over two decades of leadership in clinical development, translational medicine, and regulatory strategy across multiple therapeutic areas, including cell therapy, immunology, cardiovascular, and rare diseases.

Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced dosing of the first patient in its Phase 1 clinical trial evaluating STM-01 as a treatment for heart failure with preserved ejection fraction (HFpEF).

Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac progenitor cell (nCPC) therapy, for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF).

Secretome Therapeutics, a biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the successful closing of a $20.4 million round of financing. This funding will enable Secretome to initiate clinical trials for its lead asset, STM-01, and further advance its innovative pipeline.

Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells (nMSC) today announced the appointment of Margot Connor to its Board of Directors.

Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics derived from neonatal mesenchymal stem cells (nMSC) for the treatment of underserved diseases, today announced the appointment of Deepa Prasad as Chief Financial Officer.

Secretome Therapeutics, a preclinical company developing novel therapies derived from neonatal mesenchymal stem cells, today announced the appointment of Angela Shen, M.D., M.B.A, to its Board of Directors.